Cardium Therapeutics, Inc. (CXM) Generx Cardiovascular Solution Marches to a Different Beat

Coronary artery disease – the No. 1 cause of death worldwide – kills more than 17 million people around the world each year. It’s easy to skim over the statistics when “death” dominates global headlines. We are desensitized to a bold and ruthless serial killer among us that has literally stopped millions of hearts dead in their tracks. The real clincher is that this killer can be stopped.

Health and active living advocates have exposed cardiovascular disease for what it really is – an often self-inflicted disease that could be prevented by adhering to a healthy lifestyle. Despite an increasingly educated population, the human race, collectively, isn’t ready to forfeit poor eating choices and wise-up to heart health. That’s why regenerative medicine company Cardium Therapeutics is conducting countless hours of research and development to offer a non-conventional approach to coronary artery disease.

Traditional treatments for heart disease ranges from drug therapy to highly invasive bypass surgeries, stents, angioplasty, and grafts. Cardium’s counter solution is a one-time, non-surgical gene-based treatment option called Generx, administered using a standard cardiac infusion catheter.

Generx is designed to work with and enhance the body’s natural healing process by stimulating blood vessel growth in the heart, which in turn generates blood flow. Clinical studies of Generx show improved cardiac perfusion (blood flow, in this case) within eight weeks. To-date, Generx has completed four randomized clinical studies at more than 100 medical centers in the United States and Western Europe.

Cardium plans to enroll 100 men and women with myocardial ischemia from coronary artery disease for the upcoming ASPIRE phase 3 clinical study to evaluate the Generex’ safety and efficacy. The ASPIRE study will mark the fifth clinical study under Generex’ clinical development program, which will prepare the company to seek regulatory approval from the Russian Health Authority.

For more information, visit www.cardiumthx.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Antares Pharma, Inc. (ATRS) Receives New Drug Application Acceptance for OTREXUP

Antares Pharma announced that the U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for OTREXUP, a potential new product for subcutaneous delivery of methotrexate (MTX) using the company’s Medi-Jet technology. OTREXUP is currently being developed for MTX self-administration to enhance the treatment of rheumatoid arthritis, poly-articular-course juvenile RA, and psoriasis.

A Prescription Drug User Fee Act (PDUFA) date of Oct. 14 has been assigned by the FDA, which is 10 months from the official NDA filing, so that is the target date for the FDA to complete its NDA review of OTREXUP.

Obtaining FDA acceptance of OTREXUP marks an important start to the review process, as well as a significant milestone for Antares Pharma’s shareholders.

“We look forward to working closely with the FDA during their review of the application,” said Antares Pharma President and CEO Paul K. Wotton, Ph.D.

A proprietary parenteral drug delivery system protected by several issued and pending patents, Medi-Jet is a trademark of Antares Pharma. Medi-Jet is designed to make it quick and easy for patients to subcutaneously or intramuscularly self-administer a drug – also enhancing safety with an integrated, shielded needle to protect against accidental needle stick and drug exposure.

Used in a majority of patients, either on its own or combined with biological therapies, methotrexate is a commonly prescribed disease-modifying anti-rheumatic drug (DMARD).

For more information, visit www.antarespharma.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Online Resources Corp. (ORCC) Launches Virtual Collection Agent 5.0

Online Resources, a prominent supplier of financial technology services, announced that it has launched Virtual Collection Agent (VCA) 5.0. This new product is the most updated version of its web-based debt collections tool for financial institutions and billers of all types.

“VCA provides an online emulation of the live agent interactions that many indebted consumers would have had over the phone in the past,” explained Janie West, ORCC chief marketing officer. “It enables consumers to arrive at a payment resolution in a private, non-confrontational environment via the Internet. VCA gives consumers the full service experience they expect, but it’s all handled using intelligent automation to determine each person’s eligibility for payment plans and tailoring of payments to that consumer’s specific situation to resolve the overdue status if payment in full cannot be made immediately.”

The 5.0 version boasts a suite of new features that add value to lenders and billers as well as the consumers they serve. Companies can reduce operating costs, maximize collections, and reduce loan losses for overdue auto loans, mortgages, credit card bills, and other personal debt using VCA’s 24×7. It also simultaneously provides customers with a more effective method to restore their good account standing and eliminate the hassle of debt collection. Each biller’s eligibility rules can be used to offer customized payment programs and settlement arrangements online. The eligibility rules can be tailored around existing account data or real-time consumer information.

There are a number of exciting new features for lenders and billers, including:

– Detailed access to consumer behavior data and new, intuitive tools to control automation of online offers;

– Multi-account relationship capability with each consumer so that a single sign-on will take customers to any of their accounts that need resolution;

– Promotional code support, enabling marketing campaign and previous interaction with call center agent tracking to arrive at repayment offers specific to each consumer;

– Consumer experience in virtually any language; once consumers sign on to the site and specify their preferred language, each subsequent visit is automatically set to use that language; and

– Addresses Americans with Disabilities Act (ADA) accessibility concerns with the option to certify as WCAG 2.0 Level AA compliant.

VCA is currently collecting at a rate of $2.4 billion per year, and West points out the additional benefits to billers and lenders.

“When a $300 payment prevents a lender from charging off a $5,000 balance, that has a direct impact on an organization’s bottom line. Through champion/challenger studies, we’ve measured VCA’s average reduction in loan losses at 10 percent annually. We expect future results will identify even greater value in returning customers’ accounts to good standing – and profitability,” said West. “Organizations seeking to improve their collections would be well-served to augment their legacy methods with a tool geared toward the preferences and behaviors of today’s consumers whose primary need is to resolve the situation without embarrassment or having their schedule interrupted. Consumers simply do not want to be contacted by a live agent. With the Virtual Collection Agent 5.0, billers can collect more, for less, while restoring good, profitable relationships with their customers.”

For further information, please visit www.orcc.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

FAB Universal Corp. (FU) Sees Strong Podcast Network Growth

FAB Universal, a worldwide distributor of digital entertainment, yesterday announced that podcast download requests achieved an all-time high in the fourth quarter of 2012 with 1.6 billion for 2013 (or well over 2 billion adjusted for new algorithmic process improvements implemented the past two years). Marking a new milestone for the company, FAB Universal has nearly 5 million audience requests for podcast shows each and every day on the Libsyn Network, representing 1.7 million hours of daily content distributed in 240 countries around the world.

At the beginning of 2013, unique monthly audience members grew to over 25 million individuals, marking another milestone achievement. Following this trend, the Libsyn Network is now expected to reach over 60 million unique individuals in 2013.

Given the shift in methods through which requests were made, statistical algorithms were tweaked over the past two years with a focus on podcast consumption behavior to better account for requests from mobile devices. Approximately 50% of podcast shows are now being distributed to mobile devices such as iPhones and iPads, with iOS (Apple) devices making up 84% of mobile requests while Android accounts for 15%.

Driven by the continued expansion of content by producers, network and audience milestones have reached a new all-time high. Currently, the Libsyn Network is being used by over 13,000 paying content publishers for distribution and monetization services for over 1.1 million unique episodes. With the addition of over 1,500 shows already in 2013, new account sign-ups and revenues are also at an all-time high.

“Revenue and network numbers are up across the Libsyn podcast business and we are excited that focus on expanding recurring revenues through hosting and monetization is paying off,” commented Laurie Sims, President, Libsyn. “Steady growth in 2012 allowed us to reach new highs and proved that podcasting represents significant opportunities for revenue and audience expansion. We continue to exceed goals and enter 2013 with strong momentum to increase revenue as content, audience numbers and download requests grow. Libsyn remains the premier podcast distribution and monetization platform in the world and continues to demonstrate its dominance over all other podcast media distributors.”

For more information on FAB Universal, visit www.fabuniversal.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

CytRx Corp. (CYTR) Hits Patient Enrollment Target in Phase II Clinical Trial for Tamibarotene

CytRx is a biopharmaceutical research and development company specializing in oncology. The company’s current oncology pipeline includes two programs in clinical development for cancer indications, aldoxorubicin, and tamibarotene. It also completed evaluation of a third drug candidate, bafetinib, and is seeking a partner for further development of the drug.

The company reported today that enrollment of 140 evaluable patients has been completed in its global Phase 2b clinical trial with CytRx’s oral retinoid compound tamibarotene in combination with chemotherapeutic agents. Tamibarotene was developed to be superior to ATRA, an FDA-approved retinoid, by binding to its molecular target more selectively.

The combination will be used as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). Patients with stage IIIb or IV squamous or adenocarcinoma NSCLC who had not received prior non-adjuvant chemotherapy have been enrolled in this double-blind Phase 2b trial at sites in the United States, Mexico, India, Russia, Bulgaria, and the Ukraine.

The main goal of the clinical trial is progression-free survival. Secondary goals include response rate, overall survival, and RAR beta expression, a potential biomarker for responders.

The market for this type of cancer is decent-sized. By 2015, it is projected to be $13.3 billion. So if the trials are successful, it will be good news for CytRx, which holds the North American and European rights to certain tamibarotene intellectual property for the treatment of NSCLC. Tamibarotene is currently marketed in Japan for a rare form of leukemia.

For additional information about Cytrx Corporation, tamibarotene, and its entire portfolio of drug candidates, visit www.cytrx.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

B. Riley & Co. Helps Secure $47.9 Million for CalAmp Corp. (CAMP)

Independent investment bank B. Riley & Co. LLC has acted as joint book-running manager in a common stock offering for CalAmp, which resulted in proceeds of $47.9 million.

CalAmp intends to use the net proceeds to fund a portion of its $53 million Wireless Matrix Corp. (WSMXF, WRX.TO) acquisition, for which B. Riley is the exclusive financial advisor.

The offering, which closed February 20, 2013, consisted of 5,175,000 shares priced at $9.25 per share, including an overallotment of 675,000 shares, which the underwriters exercised in full.

Managing Director Mark Davis, Senior Vice President Salomon Kamalodine, and Associate Chris Sigala led the banking team on behalf of B. Riley.

In connection with the offering, Canaccord Genuity acted as joint book-running manager; Craig-Hallum Capital Group LLC, Northland Securities Inc. and First Analysis Securities Corp. acted as co-managers.

B. Riley’s investment banking services include merger and acquisitions advisory to public and private middle market companies, initial and secondary public offerings, and institutional private placements. The bank provides a comprehensive line of corporate finance, research, sales, trading, and otcqx dad services to corporate, institutional, and high net worth individual clients.

For more information, visit www.calamp.com or www.brileyco.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Overland Storage, Inc. (OVRL) SVP Named to CRN Channel Chief for Third Consecutive Year

Overland Storage announced yesterday that Jillian Mansolf, Senior Vice President of Global Sales and Marketing, has been named as one of CRN’S 2013 Channel Chiefs. CRN’s list recognizes executives who have driven channel sales and growth for their organization, while benefiting the entire IT industry as a whole. This is Mansolf’s third consecutive year on this prestigious list.

Channel Chiefs are selected by the CRN editorial team based on channel experience, program innovations, channel-driven revenue, and public support for the importance of IT Channel Sales. The 2013 Channel Chiefs list is featured in the 2/25/13 issue of CRN Magazine and will be featured online at www.crn.com.

Mansolf remarked, “It’s an honor to be recognized as a CRN 2013 Channel Chief, among such an influential group of IT leaders, for the third year in a row. This recognition highlights Overland’s continued dedication to providing partners with innovative solutions, as well as the best resources and out-of-the-box programs to help partners grow their business.”

Since 2009, Mansolf has spearheaded the company’s initiative to sell branded data management and data protection solutions exclusively through the worldwide channel. Under her leadership, Overland launched its first globally integrated channel program, the FastTrack Partner Program, which now has over 4,600 registered partners. The Overland FastTrack Partner Program offers integrated video training and in-person educational events to help partners stay on top of storage industry trends. The program also provides online sales and marketing tools, as well as automated deal registration and guaranteed margin protection.

Over the past year, Mansolf led the launch of Overland’s SnapSAN products and SnapScale X2, Overland’s first clustered NAS product. She also headed the development of lead generation and lead sharing programs, as well as an initiative to make global strategic end-user account sales teams available to premiere partners. This effort has won over $20 million in new opportunities for Overland partners in the second half of 2012.

For more information, visit www.overlandstorage.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

EarthLink, Inc. (ELNK) Awarded with Product of the Year Designation

EarthLink recently announced receiving the Product of the Year Award by INTERNET TELEPHONY Magazine. The award was granted for EarthLink’s Complete Hosted Voice (CPH) product.

Founded in 1994, EarthLink is focused on providing communications and IT services, including cloud computing, managed and private cloud, and virtual services such as hosting and cloud workspace. The company also maintains a portfolio of IT security, application hosting, colocation, and IT support services. EarthLink operates a network that boasts 28,800 route fiber miles with 90 metro fiber rings and 4 secure data centers which provide ubiquitous nationwide data and voice IP service coverage across more than 90% of the country.

EarthLink’s CPH is part of the EarthLink Complete suite of business, voice, and data solutions, and it integrates VoIP applications and private MPLS networks with the company’s equipment, mobile, and security offerings. Customers are able to access account management and customization via a web-based interface. INTERNET TELEPHONY 2012 Product of the Year recipients are published on the TMC website, www.tmcnet.com.

“It is with pleasure that we recognize EarthLink with a Product of the Year Award. The editors of INTERNET TELEPHONY have verified that EarthLink Complete Hosted Voice displays quality and innovation while providing solutions to real business communications challenges,” said Rich Tehrani, CEO, TMC. “I would like to congratulate the team at EarthLink for their commitment to advancing IP communication technologies.”

“Our team is pleased that TMC and INTERNET TELEPHONY magazine have again provided their vote of confidence by selecting EarthLink Complete Hosted Voice as a Product of the Year for the second time,” commented Michael Toplisek, EarthLink Executive Vice President of Sales and Marketing. “EarthLink Complete enables us to offer any size business with a single-source, full-featured Hosted IP PBX solution without the cost of purchasing a PBX. Fully scalable to grow as the customer evolves, EarthLink Complete delivers convenience and freedom so our clients can focus on their core business and spend less time managing their communications infrastructure.”

For more information, visit www.EarthLink.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

BG Medicine, Inc. (BGMD) Announces Publication of Two Studies on Galectin-3 Test

BG Medicine is a diagnostics company focused on the development and commercialization of novel cardiovascular tests. The company has two products: the Galectin-3 test for use in patients with chronic heart failure and the CardioSCORE test for the risk prediction of major cardiovascular events.

The company today announced the publication of two studies (in the United States and Europe) demonstrating the clinical utility of repeated galectin-3 testing as a useful tool in the assessment of patients with heart failure. The studies, which involved more than 3,300 subjects, demonstrated clearly that periodic evaluation of galectin-3 levels helped doctors identify those patients at greater clinical risk of a cardiac event.

Galectin-3 is a unique carbohydrate-binding lectin, or protein. It has been implicated in a variety of biological processes involved in the development and progression of heart failure. Galectin-3 is also believed to be a primary factor in abnormal thickening and stiffening of the heart muscle and in changes in the heart structure.

The company’s president and CEO, Eric Bouvier, commented on the publication of the studies, “We are very encouraged by these published results, which add to the growing body of evidence supporting thr repeated use of galectin-3 testing as an ongoing monitoring tool in the care of patients with heart failure.”

For additional information, visit www.bg-medicine.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

EXFO, Inc. (EXFO) Adds Packet Network Synchronization Testing to FTB-800 NetBlazer 2.0 Series

EXFO, a leading provider of next-generation test and service assurance solutions for wireline and wireless network operators and equipment manufacturers, yesterday announced the addition of packet synchronization testing functionalities to its NetBlazer 2.0 series. This capability expansion includes performance assessment of SyncE and precision time protocol (IEEE 1588v2), giving field technicians the capability to validate sync services during Ethernet backhaul turn-ups.

Operators can no longer rely on traditional synchronization technologies because the penetration and prevalence of LTE networks and packet-based backhaul results in a significant change of synchronization distribution throughout the network. Precision time protocol/1588 and all other new packet based synchronization technologies have caused a broad array of new challenges concerning the validation and troubleshooting processes of synchronization performance because these services are very sensitive to basic network impairments. If these impairments are left unchecked, serious consequences, such as lost data and dropped calls can precipitate.

Packet-based synchronization technologies are also used to synchronize small cells. This is a critical functionality as mobile network operators rely progressively more on small cells to effectively manage the LTE-advanced spectrum, while expanding their service coverage and increasing network capacity. In order to be successful in the future, most network operators will require the ability to turn up, validate, and troubleshoot packet-based services quicker and more accurately than ever before, as the number of small cells shipped annually swells to five million by 2017.

Thanks to its added synchronization testing functionalities, the NetBlazer 2.0 series now provides operators with such flexibility and adaptability to overcome their cell-site deployment challenges. And combined with the SyncWatch-110 Synchronization Test Unit, it makes for a complete packet-synchronization testing and monitoring solution that delivers detailed and accurate sync validation throughout the network lifecycle.

“With the proliferation of LTE networks, small cells and Ethernet backhaul links, packet-synchronization validation is becoming a major concern for operators. Being able to test and troubleshoot all these services with one comprehensive tool gives them the flexibility to adapt their operational processes and make their field teams as efficient as possible,” said Étienne Gagnon, Vice-President of EXFO’s Test and Measurement Division.

For further information, visit www.EXFO.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

ANADIGICS, Inc. (ANAD) Announces Plans for ProEficient Solution to Power Samsung Galaxy Music Duos and Chat

ANADIGICS, a world leader in radio frequency (RF) solutions, today announced plans to ship production volumes of its AWT6651 ProEficient™ power amplifier (PA) to Samsung Electronics for the Galaxy Music Duos and Chat. Featuring a 3-inch touch screen, the Galaxy Music Duos S6012 boasts an 850 MHz processor and 4 GB of storage. The Galaxy Chat B5330 offers a QWERTY keyboard, 3-inch touch screen, and 850 MHz processor. The Android™ 4.0 Ice Cream Sandwich operating system is included on both phones.

“ANADIGICS’ ProEficient and ProEficient-Plus™ power amplifiers provide the industry’s best combination of efficiency, current consumption, and linearity to help extend battery-life and maintain stable, high throughput 4G connectivity,” commented Michael Canonico, senior vice president of Worldwide Sales at ANADIGICS. “The selection of the AWT6651 for the Galaxy Music Duos and Chat not only exemplifies the tremendous real-world performance advantages offered by our ProEficient solutions, but also the strength of the relationship that we have forged with Samsung Electronics. We look forward to continued close collaboration with Samsung in the design of next-generation mobile devices that further the user experience.”

Using the ANADIGICS’ exclusive InGaP-Plus™ technology, its ProEfficient power amplifiers achieve outstanding efficiency at high and low power modes to extend 3G and 4G battery-life without the use of a DC-DC converter. By being optimized for use with average power tracking (APT), these power amplifiers further increase efficiency and reduce current consumption at medium and low operating powers. ProEficient power amplifiers deliver exceptional linearity to ensure a stable connection for clear voice and high-speed data while also providing outstanding efficiency.

For more information on ANADIGICS, visit www.anadigics.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

High Expectations Set for Chanticleer Holdings, Inc. (HOTR) Growth Initiatives

Franchisee of international Hooters restaurants and minority owner in the privately held Hooters of America, Chanticleer Holdings is presently the only entity through which Hooters fans can easily purchase stock in the famous fun-time restaurant they love. With big developments on the horizon, it’s shaping up to be a good year for Chanticleer and Hooters as they head further into 2013.

With a focus on achieving same store sales growth, improving consolidated gross margin to 62 percent from 58.2 percent, increasing overall profitability, and expanding the number of Hooters restaurants it owns and operates, Chanticleer is taking steps toward a very prosperous year.

Currently, Chanticleer has exclusive franchise rights to open and operate Hooters restaurants in South Africa, Hungary, and parts of Brazil. The company has also joint ventured with the owner of exclusive Hooters franchise rights in Australia. Chanticleer currently owns and operates, in whole or in part, six Hooters restaurants, and that number is set to increase to 10 during 2013. The company’s current Hooters restaurants are located in Durban, Johannesburg, Cape Town, and Emperor’s Palace in South Africa; Budapest in Hungary; and Campbelltown in Australia. Among locations planned to be opened this year is a long-awaited Hooters restaurant in Rio de Janeiro, Brazil; another in Pretoria, South Africa; and one in Surfer’s Paradise, Australia.

In its South Africa restaurants, Chanticleer has already taken steps toward improving same store sales growth and gross margin, having implemented price increases on food and liquor that still reflect competitive pricing in the current market. Menu offerings have been updated for Hooters South Africa locations, with the removal of slow-selling items and the addition of new menu items that appeal to women – including two new salads, expanded wrap offerings, a “ladies cut” steak, and the option for guests to purchase a smaller portion of curly fries with their main course. The company is also enhancing the appeal of its restaurants for customers, having increased the seating availability in its Durban restaurant to accommodate busy weekends and large groups, and having invested in additional televisions to improve the guest experience at its Johannesburg location. The company experienced same store sales growth in South Africa for 2012 and anticipates further improvement this year.

Chanticleer is also making strides toward reducing costs, increasing profitability, and boosting guest traffic at its Hooters of Budapest location. During this first quarter of 2013, Hooters of Budapest is launching its Efficient Operation Network – a tool developed to lower sales costs and labor costs and improve overall operational efficiency. That restaurant is also hosting first-time events to increase guest traffic, including a tequila party, bike night, and the recently celebrated Valentine’s Day Blowout. Hooters of Budapest is also launching a “Girls of Budapest” pictorial and plans to open its outdoor patio this year in time for the thriving Budapest tourist season (April through October); this will add 140 seats to the restaurant, increasing total seating by 56 percent.

For more information about purchasing ownership in Hooters, visit www.chanticleerholdings.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Cytori Therapeutics, Inc. (CYTX) Appoints Chief Medical Officer

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Data suggest that ADRCs improve blood flow, moderate the inflammatory response, and keep tissue at risk of dying alive.

The company today announced the appointment of Steven Kesten, MD, as executive vice-president and chief medical officer. In this role, Dr. Kesten will lead Cytori’s global clinical development operations and its Medical Affairs activities. His job will be to strengthen the company’s clinical program, starting with its cardiovascular business and then expanding into other therapeutic areas.

Dr. Kesten is a seasoned physician executive with more than 30 years’ experience in medicine. He recently served as vice-president and CMO at Uptake Medical. While in those positions, Dr. Kesten oversaw the completion of the VAPOR trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical’s device, InterVapor.

Prior to that stint, Dr. Kesten served for more than 10 years at Boehringer Ingelheim, most recently as Vice President in Medicine for Marketed Products for respiratory disease. While in that role, he was responsible for the development and execution of multiple large-scale clinical trials and was at the point in the global registration and branding of the $3 billion drug Spiriva.

Additionally, Dr. Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant program to Rush Presbyterian St. Luke’s Medical College in Chicago. He received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.

For further information about Cytori Therapeutics, visit www.cytori.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

EXFO, Inc. (EXFO) Adds Packet Network Synchronization Testing to FTB-800 NetBlazer 2.0 Series

EXFO, a leading provider of next-generation test and service assurance solutions for wireline and wireless network operators and equipment manufacturers, yesterday announced the addition of packet synchronization testing functionalities to its NetBlazer 2.0 series. This capability expansion includes performance assessment of SyncE and precision time protocol (IEEE 1588v2), giving field technicians the capability to validate sync services during Ethernet backhaul turn-ups.

Operators can no longer rely on traditional synchronization technologies because the penetration and prevalence of LTE networks and packet-based backhaul results in a significant change of synchronization distribution throughout the network. Precision time protocol/1588 and all other new packet based synchronization technologies have caused a broad array of new challenges concerning the validation and troubleshooting processes of synchronization performance because these services are very sensitive to basic network impairments. If these impairments are left unchecked, serious consequences, such as lost data and dropped calls can precipitate.

Packet-based synchronization technologies are also used to synchronize small cells. This is a critical functionality as mobile network operators rely progressively more on small cells to effectively manage the LTE-advanced spectrum, while expanding their service coverage and increasing network capacity. In order to be successful in the future, most network operators will require the ability to turn up, validate, and troubleshoot packet-based services quicker and more accurately than ever before, as the number of small cells shipped annually swells to five million by 2017.

Thanks to its added synchronization testing functionalities, the NetBlazer 2.0 series now provides operators with such flexibility and adaptability to overcome their cell-site deployment challenges. And combined with the SyncWatch-110 Synchronization Test Unit, it makes for a complete packet-synchronization testing and monitoring solution that delivers detailed and accurate sync validation throughout the network lifecycle.

“With the proliferation of LTE networks, small cells and Ethernet backhaul links, packet-synchronization validation is becoming a major concern for operators. Being able to test and troubleshoot all these services with one comprehensive tool gives them the flexibility to adapt their operational processes and make their field teams as efficient as possible,” said Étienne Gagnon, Vice-President of EXFO’s Test and Measurement Division.

For further information, visit www.EXFO.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

ANADIGICS, Inc. (ANAD) Announces Plans for ProEficient Solution to Power Samsung Galaxy Music Duos and Chat

ANADIGICS, a world leader in radio frequency (RF) solutions, today announced plans to ship production volumes of its AWT6651 ProEficient™ power amplifier (PA) to Samsung Electronics for the Galaxy Music Duos and Chat. Featuring a 3-inch touch screen, the Galaxy Music Duos S6012 boasts an 850 MHz processor and 4 GB of storage. The Galaxy Chat B5330 offers a QWERTY keyboard, 3-inch touch screen, and 850 MHz processor. The Android™ 4.0 Ice Cream Sandwich operating system is included on both phones.

“ANADIGICS’ ProEficient and ProEficient-Plus™ power amplifiers provide the industry’s best combination of efficiency, current consumption, and linearity to help extend battery-life and maintain stable, high throughput 4G connectivity,” commented Michael Canonico, senior vice president of Worldwide Sales at ANADIGICS. “The selection of the AWT6651 for the Galaxy Music Duos and Chat not only exemplifies the tremendous real-world performance advantages offered by our ProEficient solutions, but also the strength of the relationship that we have forged with Samsung Electronics. We look forward to continued close collaboration with Samsung in the design of next-generation mobile devices that further the user experience.”

Using the ANADIGICS’ exclusive InGaP-Plus™ technology, its ProEfficient power amplifiers achieve outstanding efficiency at high and low power modes to extend 3G and 4G battery-life without the use of a DC-DC converter. By being optimized for use with average power tracking (APT), these power amplifiers further increase efficiency and reduce current consumption at medium and low operating powers. ProEficient power amplifiers deliver exceptional linearity to ensure a stable connection for clear voice and high-speed data while also providing outstanding efficiency.

For more information on ANADIGICS, visit www.anadigics.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

High Expectations Set for Chanticleer Holdings, Inc. (HOTR) Growth Initiatives

Franchisee of international Hooters restaurants and minority owner in the privately held Hooters of America, Chanticleer Holdings is presently the only entity through which Hooters fans can easily purchase stock in the famous fun-time restaurant they love. With big developments on the horizon, it’s shaping up to be a good year for Chanticleer and Hooters as they head further into 2013.

With a focus on achieving same store sales growth, improving consolidated gross margin to 62 percent from 58.2 percent, increasing overall profitability, and expanding the number of Hooters restaurants it owns and operates, Chanticleer is taking steps toward a very prosperous year.

Currently, Chanticleer has exclusive franchise rights to open and operate Hooters restaurants in South Africa, Hungary, and parts of Brazil. The company has also joint ventured with the owner of exclusive Hooters franchise rights in Australia. Chanticleer currently owns and operates, in whole or in part, six Hooters restaurants, and that number is set to increase to 10 during 2013. The company’s current Hooters restaurants are located in Durban, Johannesburg, Cape Town, and Emperor’s Palace in South Africa; Budapest in Hungary; and Campbelltown in Australia. Among locations planned to be opened this year is a long-awaited Hooters restaurant in Rio de Janeiro, Brazil; another in Pretoria, South Africa; and one in Surfer’s Paradise, Australia.

In its South Africa restaurants, Chanticleer has already taken steps toward improving same store sales growth and gross margin, having implemented price increases on food and liquor that still reflect competitive pricing in the current market. Menu offerings have been updated for Hooters South Africa locations, with the removal of slow-selling items and the addition of new menu items that appeal to women – including two new salads, expanded wrap offerings, a “ladies cut” steak, and the option for guests to purchase a smaller portion of curly fries with their main course. The company is also enhancing the appeal of its restaurants for customers, having increased the seating availability in its Durban restaurant to accommodate busy weekends and large groups, and having invested in additional televisions to improve the guest experience at its Johannesburg location. The company experienced same store sales growth in South Africa for 2012 and anticipates further improvement this year.

Chanticleer is also making strides toward reducing costs, increasing profitability, and boosting guest traffic at its Hooters of Budapest location. During this first quarter of 2013, Hooters of Budapest is launching its Efficient Operation Network – a tool developed to lower sales costs and labor costs and improve overall operational efficiency. That restaurant is also hosting first-time events to increase guest traffic, including a tequila party, bike night, and the recently celebrated Valentine’s Day Blowout. Hooters of Budapest is also launching a “Girls of Budapest” pictorial and plans to open its outdoor patio this year in time for the thriving Budapest tourist season (April through October); this will add 140 seats to the restaurant, increasing total seating by 56 percent.

For more information about purchasing ownership in Hooters, visit www.chanticleerholdings.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Cytori Therapeutics, Inc. (CYTX) Appoints Chief Medical Officer

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Data suggest that ADRCs improve blood flow, moderate the inflammatory response, and keep tissue at risk of dying alive.

The company today announced the appointment of Steven Kesten, MD, as executive vice-president and chief medical officer. In this role, Dr. Kesten will lead Cytori’s global clinical development operations and its Medical Affairs activities. His job will be to strengthen the company’s clinical program, starting with its cardiovascular business and then expanding into other therapeutic areas.

Dr. Kesten is a seasoned physician executive with more than 30 years’ experience in medicine. He recently served as vice-president and CMO at Uptake Medical. While in those positions, Dr. Kesten oversaw the completion of the VAPOR trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical’s device, InterVapor.

Prior to that stint, Dr. Kesten served for more than 10 years at Boehringer Ingelheim, most recently as Vice President in Medicine for Marketed Products for respiratory disease. While in that role, he was responsible for the development and execution of multiple large-scale clinical trials and was at the point in the global registration and branding of the $3 billion drug Spiriva.

Additionally, Dr. Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant program to Rush Presbyterian St. Luke’s Medical College in Chicago. He received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.

For further information about Cytori Therapeutics, visit www.cytori.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Synthetic Biologics, Inc. (SYN) Flupirtine Sublicensee Receives FDA Green Light for Phase II Fibromyalgia Clinical Trial in U.S.

Friday, synthetic biologics and innovative medicine developer Synthetic Biologics announced that Meda AB, its flupirtine sublicensee, has been given a green light by the U.S. Food and Drug Administration to conduct a Phase II proof of concept study for the treatment of fibromyalgia, as reported in Meda’s year-end report for 2012. The randomized, double-blind, placebo and active-controlled study of fibromyalgia patients will be conducted at 25 U.S. clinics, as reported by Meda.

In May of 2010, Synthetic Biologics entered into an agreement with Meda, a company based in Sweden, granting exclusive sublicense to all of its patents and pending patents that cover the use of flupirtine for fibromyalgia in the United States, Canada, and Japan. Meda assumed all future development costs for commercializing flupirtine for fibromyalgia. Synthetic Biologics was given an upfront payment and is entitled to future milestone payments and royalties.

A chronic and debilitating condition, fibromyalgia is characterized by pain and stiffness throughout the body, as well as severe fatigue, insomnia, and mood symptoms. Approximately 3 to 6 percent of the global population is affected by fibromyalgia, including around 10 million patients in the United States. Currently, three products have been approved for this indication in the U.S. – Lyrica, Cymbalta, and Savella. Flupirtine is different from these products in that it uses a unique mode of action.

A first-in-class, novel type of central nervous system agent known as a selective neuronal potassium channel opener, flupirtine has NMDA receptor agonist properties. It is currently approved and marketed by Meda for pain treatment in several countries outside of the U.S.

“We are pleased to share Meda’s update on the status of its clinical development program of flupirtine for fibromyalgia,” said Synthetic Biologics CEO Jeffrey Riley. “We believe Meda’s experience with flupirtine outside of the U.S. will help bring this potential new class of treatment to the millions of people that suffer from fibromyalgia in the U.S.”

A biotechnology company, Synthetic Biologics is focused on developing product candidates for serious infections and diseases. The company is developing a biologic for the prevention of C. difficile infection, as well as a series of monoclonal antibodies to treat serious infectious diseases, such as pertussis and Acinetobacter. Synthetic Biologics is developing a synthetic DNA-based therapy for treating pulmonary arterial hypertension, as well as a drug candidate for treating relapsing-remitting multiple sclerosis and cognitive dysfunction in MS. The company is additionally designing a clinical development pathway for treating amyotrophic lateral sclerosis, in addition to its partnership with Meda AB for the development of a fibromyalgia treatment.

For more information, visit www.syntheticbiologics.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

GT Advanced Technologies, Inc. (GTAT) Appoints VP to Lead New Growth

GT Advanced Technologies made an announcement regarding some of its newest developments. The company announced that Linda Reinhard has been appointed as vice president, new business development, and product management for the GT’s sapphire, DSS™, and HiCz™ products. Reinhard will lead GT’s growth into new market segments, driving the product roadmap to capitalize on new opportunities. She will report to chief operating officer, Dan Squiller.

Reinhard has over two decades of experience with leading technology companies including Motorola, Cisco, Nokia, and H-P, holding senior level positions in new business development, marketing, sales, and product management. She has lived in Asia and spent much time evangelizing and introducing new products to major OEMs in China and other Asian markets. She holds a BSEE from University of Illinois and an MBA from The Kellogg Graduate School of Management.

“Linda brings deep experience and a proven track record in both product management and new business development,” said Squiller. “Linda’s initial focus will be on growing our sapphire material and ASF equipment business, particularly new opportunities in the cover and touch screen markets. She has extensive experience in Asia as well as in the mobile device segment which we believe could be a significant area of opportunity for our sapphire business. Linda will also drive our product management and new business development for HiCz and our traditional PV business.”

In the same announcement, GT revealed that it will be showcasing its cover and touch screen sapphire material in the 2013 Mobile World Congress, the world’s largest mobile device event. The event takes place from February 25-28 in Barcelona, Spain. GT will be exhibiting at MWC in Hall 5 Stand 5D32.

“Our goal for the show is to continue educating the market about the unique properties of GT’s ASF-grown sapphire material for cover and touch screen applications,” remarked Reinhard. “ASF-grown sapphire’s durability and resistance to scratching makes it ideally suited for a wide range of cover and touch screen applications from ruggedized phones, camera covers, point of sale devices and smartphone and touch screen devices. Other reinforced glass and cover screen technologies try to emulate what ASF-grown sapphire does naturally.”

For more information, visit www.gtat.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Local Corp. (LOCM) Video Chart for Monday, February 25, 2013

LOCM is holding a base at $1.62 and closed ahead on Friday by 5.5 percent at $1.72. The indicators are giving early signs of a possible reversal in the chart, but have given “head fakes” in the recent past, so technical traders will be particularly keen to the bottom support and looking ahead towards resistance at $2.00 on any sustained upward push.

To view the video chart, visit the following link: http://www.missionir.com/videos.html

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Duma Energy Corp. (DUMA) is “One to Watch”

Duma Energy Corp. is an aggressive growth company actively producing oil and gas in the domestic United States, both on and offshore. Leveraging its technical expertise, promising portfolio, and strong financial condition, the company plans to utilize domestic revenues and cash flow to fund its rapid growth through acquisition, while participating in transformational projects with the potential of providing exponential returns for shareholders.

The company’s primary goal for fiscal year 2013 and beyond is to drive earnings growth. The company also aims to pursue listing on major exchange(s) to provide better visibility and liquidity to shareholders and financial partners. Already producing and generating revenue from oil and gas in Texas, Illinois, and Louisiana, Duma projects domestic production to exceed 2,500 boepd projected by the end of 2013.

Duma was founded in 2005 and began trading on the OTCBB in 2009 via registration. In 2006, the company began producing from its first properties in Texas and soon after added production in Louisiana. In 2009, its new CEO Jeremy G. Driver came on board. Within one year, Mr. Driver had identified and negotiated an acquisition that would fundamentally reshape the company. This acquisition was made possible by the large direct cash investment by Mr. Driver and his family, as well as other investors.

The company uses only industry standard and time-tested technologies, and avoids unproven “resource plays” and other opportunities that are heavily dependent upon high commodity prices. Not bound by any geographical location or operational strategy, Duma’s management team is focused on developing its existing portfolio while pursuing additional opportunities that provide rapid growth, leveraging growing revenue, cash flow, and reserves to accelerate its growth strategy.

For more information on Duma Energy, please visit www.DUMA.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

GlobalWise Investments, Inc. (GWIV) and the Disappearing Computer

Long ago, the term “computer” simply represented a human being who did calculations for an insurance company or other large public or private organization. Later it meant a machine the size of a large room that was able to spit out all of the numbers that used to be calculated by people. Then it meant a smaller machine that did a lot more, and eventually machines we could sit on our desktops and laps.

Today the term computer is losing its meaning, since computer power is becoming disseminated, embedded in all types of devices in every aspect of modern industrial life. As such, the demand for what was once the domain of the computer is increasingly being directed toward a mobile environment, where work is being done on the road instead of in the office. It’s a shift that is driving a revolution, as the computer slowly disappears, being replaced by on-demand cloud enabled access from anywhere at any time.

Intellinetics, a subsidiary of GlobalWise, represents a unique step in this direction through the offering of their Intellivue Document Management Platform for Enterprise Content Management. Organizations are anxiously trying to regain control over increasing workflows in order to avoid serious redundancy, security, and compliance issues, and yet the majority of their documents often lie trapped as unstructured data.

Through key partnerships with business software and hardware resellers, Intellivue document capturing and indexing capabilities become a seamless part of normal business processes, allowing organizations of all types to quickly and effortlessly capture previously unstructured paper documents, providing a rich new world of process-ready information. But the best part is that all of this is available in a cloud configuration, allowing authorized data access on a 24/7 basis from virtually anywhere in the world. Ironically, as the computer slowly disappears into the cloud, companies like GlobalWise and Intellinetics are ensuring that all of the power it has come to represent continues to grow.

For additional information, visit www.GlobalWiseInvestments.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Pendrell Corp. (PCO) Acquires 68% Stake in Provitro Biosciences

Pendrell, through its subsidiaries, is a fully integrated intellectual property investment advisory services and asset management firm. The company seeks to invest in or acquire assets that represent not only unique intellectual property rights, but also outstanding growth potential.

The company announced today that it has acquired a 68% stake in Provitro Biosciences. This firm is a world leader in commercial-scale plant propagation methods. Pendrell’s investment will enable Provitro to develop the vast commercial potential for a number of breakthrough advances being developed by the company.

Provitro pioneered the development of an innovative, proprietary micropropagation method that advances the rising demand for renewable and sustainable plant production on a mass scale without genetic modifications. Global markets for Provitro involve a number of industries including pulp, paper, energy, food, textile, and the plant nursery industry.

Worldwide interest and demand for sustainable, renewable plant sources is growing rapidly. Provitro has initially focused on bamboo. It already sells ornamental bamboo through Home Depot and Costco. Last year, the company entered into a first of its kind development agreement with Kimberly Clark, which is exploring the manufacturing of tissue products containing fiber from the company’s proprietary bamboo propagation technology.

For additional information about Pendrell and Provitro Biosciences, please visit www.pendrell.com and www.provitrobio.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

CAMAC Energy, Inc. (CAK) Secures Top Airborne Geophysical Survey Firm for Gravity and Magnetic Work

CAMAC Energy, the U.S.-based hydrocarbon developer with a substantial portfolio of onshore and offshore interests in Africa, including their deep water oil and gas leases offshore of Nigeria, reported today that the company has inked an agreement with noted gravity, magnetic total field, magnetic gradient, and radiometric survey specialists, Sander Geophysics Limited (SGL), to handle geophysical surveying at the company’s onshore Blocks L1B and L16 in Kenya.

Senior VP of E&P for CAK, Segun Omidele, expressed supreme confidence in the deal struck with SGL and called the agreement a major milestone for the company’s Kenyan operations. Not only will this analytical work more than cover the bases set out for the first exploration period, it will enable the company to rationalize a fully-optimized implementation for their forthcoming 2D seismic program, thanks to the clear flagging of basement structures in the geology, as well as faults, and features like the intrusions and intra-sedimentary volcanic layers.

SGL has a battery of airborne gravity and magnetic geophysical work all lined up for the massive, approximately 4,709 square mile Block L1B, as well as for the 1,394 square mile Block L16. Such an effort will far outstrip initial survey requirements slated for the first exploration period, and CAK is extremely confident in the results that will come out of this 57-year veteran global provider of airborne geophysical surveying. Indeed, SGL has quite a reputation in the sector for doing both petroleum and mineral exploration work like this. The firm has seen operational activity on every continent this planet has to offer, including Antarctica, often shrugging off the difficulties of climate and locale via the superior skill of its employees and an obvious mastery of the fundamental aircraft and technical logistics required. The Ottawa-based SGL is well-known throughout the sector for their specially modified fixed-wing aircraft, as well as helicopter-executed digital elevation modeling, driven by output from the firm’s scanning LiDAR (light detection and ranging) systems, in conjunction with radar and laser profiler datasets.

We are looking at a Q2 2013 timetable for kick off by SGL on the surveying, with analytical results from the data collection coming back the following quarter, and markets will be eager to get a more detailed look at the potential of CAK’s considerable acreage position in underexplored Kenya at that time. There are four huge sedimentary basins in Kenya and even now the level of activity is nowhere near capacity, so CAK has plenty of room to expand here despite the influx in recent years of major sector players. CAK has signed production sharing contracts with the Kenyan Ministry of Energy (named operator, 100% net interest, Kenyan government option for up to 20% development participation), and when you stack the potential here up against the company’s successful offshore interests in the western part of the continent (Oyo Field in Nigeria and Gambia’s A2 and A5 concessions), it is little wonder that the investment community is buzzing about CAMAC Energy.

For more information on CAMAC Energy, visit www.CamacEnergy.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Alvarion® Ltd. (ALVR) Broadband Wireless Access Division to be Acquired by Telrad Networks

Alvarion, a provider of highly optimized wireless broadband capabilities with a portfolio of solutions spanning across licensed and unlicensed spectrums, was reported today by leading private global telecom solutions provider, Telrad Networks, as having agreed to Telrad’s $6.1M acquisition offer on ALVR’s broadband wireless access (BWA) division.

In addition to the reported sticker price, the deal also stipulates that Alvarion may receive performance-based milestone payments up to $6M, which isn’t much of a leap of faith, considering the burgeoning growth of BWA technology across the massive global wireless broadband space. The incredibly transformative effect of disseminating internet access via such technology to locations all over the planet that have little to no infrastructure is profound indeed and thus the giant movements within the sector in recent years.

Alvarion’s BreezeCOMPACT is a perfect representation of this new tech paradigm’s potential, offering providers a self-contained and extremely robust outdoor unit with a small footprint that is easily deployed and yet packs everything needed to execute a super-fast wireless broadband node all in one box. Better yet, the design is future-proofed with LTE-Advanced onboard and utilizes software-defined radio design, making this the perfect device for hitting a whole slew of supported frequencies (16e, 16e+, and LTE-A). Macro base station class performance from a tight little single-box architecture allows for modular deployment and scalable coverage footprints, something which has led to ALVR’s globe-spanning BWA division growing to over 250 current broadband carriers, as well as wireless internet service providers. Furthermore, BreezeCOMPACT makes great use of ALVR’s extremely mature and field-proven, all-IP 4Motion™ technology, which provides operators with a level of situational awareness via high interoperability and immersion in a complete ecosystem at the network level, that allows for an optimal responsiveness to emerging device and service trends.

CEO of Telrad, Ran Bukshpan, underscored the broad synergies inherent in the deal, as each company is heavily enmeshed in essentially parallel technical areas. They also have much in common when it comes to end-market engagement dynamics. It’s a natural fit really and because both firms already have an established global presence in the overall market, doing business with the same types of customers around the world, the resulting entity will be poised to capture massive territory as the rush into next-gen wireless heats up.

Bukshpan projected strong returns from BWA as an aggressive roadmap for development has already been laid out for migrating customers smoothly into the new, more powerful TD-LTE (Time-Division Long-Term Evolution) Advanced environment. Bukshpan welcomed the new personnel who will be coming over from ALVR heartily and pledged to continue serving the “impressive customer base” already established by Alvarion with the same level of consistent, dedicated customer service for which Telrad is so well-liked by their enterprise telecom clientele.

The deal is huge for ALVR and also puts the already well-positioned Telrad in the pole position to dominate substantial territory in broadband wireless access innovation. The marriage of these two entities will no doubt continue to produce newsworthy events for investors to keep track of as the stampede into the LTE-Advanced 4G standard goes hypernova, especially in emerging markets where mobile adoption by consumers is strikingly above average.

Telrad’s might as an established equipment vendor and services company, providing over 100 top global telecom operators and enterprises with all the implementation, management, and provisioning help they need to get the job done, will serve as a major springboard for ALVR’s ground-breaking product portfolio.

For more information on Alvarion, please visit www.Alvarion.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Wireless Ronin Technologies, Inc. (RNIN) Releases Next Generation of RoninCast 4.0

Wireless Ronin Technologies, a digital marketing technologies company, recently released the fourth generation of its RoninCast® software, which is designed to increase functionality and improve the customer experience while simultaneously reducing installation and operation costs.

Wireless Ronin’s proprietary RoninCast 4.0 software, continuing to expand on the omni-channel offering launched in 2011, now leverages HTML5 capabilities, providing a more cost-effective delivery of robust digital content to current and emerging marketing technology platforms including digital signage, interactive kiosk, mobile, social, and web. With the ability to use lower cost players along with decreased network demand and server requirements, the new browser-based functionality also drives ROI.

RoninCast 4.0 also features further integration of mobile devices with in-store digital technologies, enabling customers to engage with the brand using their own mobile tablet or smartphone. Filtering a fast food menu for allergens, playing an interactive game while waiting for services at a store, or downloading dynamic coupons from a digital display are just a few examples of new application capabilities. The addition of these new capabilities allow companies to improve the customer experience, drive purchase decisions, and deliver more relevant offers which, ultimately, increase loyalty and drive sales.

RoninCast 4.0′s new patent-pending content validation technology uses a heuristic, algorithmic process that ensures timely and accurate content playback. This, in turn, ensures that the correct content is always playing on the designated device. The software also continually monitors both the player and display, sending alerts regarding discrepancies identified by the algorithm.

Additional upgrades and improved usability features for RoninCast 4.0′s new RSS feed widgets include specific zone-based scheduling, enhanced cache management, cloud-based or on-site hosted solutions, and a remote installation option.

“This new release demonstrates our commitment to continued technology investments to bring our customers unmatched digital marketing functionality,” commented Scott Koller, Wireless Ronin’s president and CEO. “With these key enhancements, our customers can accelerate and drive ROI. Given its lighter hardware and bandwidth requirements, we estimate RoninCast 4.0 can substantially reduce the initial investment and typical payback period. RoninCast 4.0 will continue to set our digital marketing solutions platform apart from the competition, paving the way for broader adoption by existing customers and generating new customer wins.”

Scheduled for release in March 2013, RoninCast 4.0 will be publicly debuted at the world’s largest international interactive display exhibition, Digital Signage Expo (DSE), February 26-28, 2013, in Las Vegas.

For more information on Wireless Ronin Technologies, visit www.wirelessronin.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

ANADIGICS, Inc. (ANAD) Grows Frequency Band Range of Small-Cell Power Amplifier Family

ANADIGICS, a global radio frequency (RF) solutions leader, introduced its AWB7224 small-cell power amplifier (PA) today. This innovative new product is designed to provide the industry’s best combination of efficiency, linearity, output power, and thermal characteristics for WCDMA, HSPA, and LTE small-cell base stations operating in a frequency range of 728 to 768 MHz. Manufacturers can utilize this powerful new amplifier to create infrastructure solutions that deliver higher throughput and greater coverage, while consuming less power.

“ANADIGICS continues to expand its family of small-cell power amplifiers to target the 3G and 4G frequency bands most used in dense population areas,” said Glenn Eswein, director of product marketing for infrastructure products at ANADIGICS. “The rapid increase in wireless data consumption, especially in urban and campus settings, places tremendous pressure on existing wireless infrastructure. Our solutions enable the design of high throughput, reliable, and compact small-cell base stations that offer service providers an economical and pragmatic path to expand broadband network coverage.”

The foundation of ANADIGICS’ small-cell wireless infrastructure power amplifiers is the company’s proprietary InGaP-Plus™ technology and advanced design architectures. It is this powerful combination that allows the AWB7224 to deliver world-class performance and integration while offering 13% efficiency to minimize power requirements and provide flexibility in selecting network power systems.

The AWB7224 enables high throughput data rates with a very broad coverage area with extraordinary linearity of -47 dBc ACPR at +27 dBm output power, and 29 dB of RF gain. The entire suite of small-cell power amplifiers is available in a compact, low profile 7 mm x 7 mm x 1.3 mm surface mount package featuring integrated RF matching to shrink PCB space requirements.

For further information, please visit www.anadigics.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

VistaGen Therapeutics, Inc. (VSTA) and the Rising Cost of Medicines

If there is one thing that seems to define modern health care, it’s costs. Today, there are options that never had to be considered in the past, but options that come at a price. High-tech healthcare costs money, but most people are also glad to have such options available and wouldn’t want to go back to the old days. However, there is one area of cost that is especially controversial. The fast rising cost of pharmaceuticals is difficult for most people to appreciate. After all, one pill looks pretty much like another. But the pharmaceutical industry is quick to point out a range of factors that have fed the frightening increase in the price paid for these pills.

First and foremost is the exploding cost of research and development. One study suggests that the average cost of bringing a new drug to market has risen from $199 million in the 1970s, itself an impressive figure, to almost $1.9 billion. Further studies suggest that this 10-fold jump is due to several factors, including more time spent in clinical testing plus stricter regulations that can end up ruining years of research. The fact is drug development is far riskier today, with the chances of success much smaller than they used to be. It takes twice as long to get an approval, and the odds of getting approved at all are only about one in ten.

VistaGen Therapeutics offers a major source of help in potentially reducing these costs. The company has used its advanced proprietary stem cell technology to create a unique testing platform for new drug development called Human Clinical Trials in a Test Tube. It will allow drug development companies to greatly reduce the risks involved in drug development by giving them a way to test drugs on real human tissues while still in the lab, long before any clinical trials. Companies can thereby avoid the chance of spending huge amounts of money developing a drug only to have it get pulled in clinical trials due to heart or liver toxicity.

For additional information, visit www.VistaGen.com


About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html